Fig. 6From: Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariablesIntegration of “high” or “low” blood-based pre-vaccination immune-capabilities with a scoring system. a Audencel patients with “high” immune-capabilities have a significantly longer PFS (p < 0.001, n = 43) and (b) OS (p = 0.014, n = 43)Back to article page